• Blocking IL-17 at the receptor level

    Is it possible to prevent inflammatory signalling of multiple IL-17 cytokines expressed in psoriatic skin?
    Find out more about IL-17 inhibition.

  • Aiming for PASI 100

    Three biologics targeting IL-17 have received EMA and FDA approval for the treatment of moderate-to-severe plaque psoriasis. Secukinumab and ixekizumab target the IL-17A molecule itself, while brodalumab is the first and only to selectively target the IL-17 receptor subunit A. See how these treatments performed in their clinical trial programmes regarding complete disease resolution.

 

IL-17 and psoriasis

Psoriasis is a chronic, painful, disfiguring and disabling disease which affects 125 million people (Ortonne & Prinz, 2004; Menter et al., 2008; World Health Organisation, 2016; The International Federation of Psoriasis Associations, 2017). Inflammation within the skin causes hyperproliferation of keratinocytes, and results in skin scaling and thickening, itching and erythema (Baliwag et al., 2015). Patients with psoriasis are also at an increased risk of several comorbidities, including cardiovascular and metabolic diseases, with psoriasis frequently having a profoundly negative effect on patients’ quality of life (Feldman et al, 2015; Menter et al, 2008).

Take a look through the IL-17 and psoriasis Learning Zone as we focus on the role of IL-17 family in psoriasis pathophysiology and review how disease severity is assessed and how modern biologics allow us to aim higher and target complete skin clearance. Also, explore the key clinical trial data for anti-IL-17 biologics in psoriasis and find out what the experts think of them.

Targeting IL-17 to treat psoriasis

Targeting IL-17 to treat psoriasis

IL-17 plays a central role in the psoriatic inflammatory process. Discover the mechanism of action of the different biologics targeting the IL-17 pathway.

Aiming for PASI 100

Aiming for PASI 100

We need to aim higher when treating patients with psoriasis. Achieving PASI 100 is key to improving patient quality of life.

 

Login/ Register Maximise Minimise

Alternatively login via